InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,185.20
(
0.09%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.25
(
0.15%
)
Bitcoin
65,901.15
(
-1.11%
)
Post# of 252220
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ghmm

Send PM Follow Ignore
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

ghmm

Re: DewDiligence post# 217941

Thursday, 03/15/2018 7:23:44 PM

Thursday, March 15, 2018 7:23:44 PM

Post# of 252220
Thanks for the information!

Yes both are intended for both FDA and EMA filings.
QURE's isn't posted yet but here are (both) BMRN's (second is low dose and will have 3rd with patients with existing AAV5 antibodies
https://clinicaltrials.gov/ct2/show/study/NCT03370913
https://clinicaltrials.gov/ct2/show/study/NCT03392974


With how much factor level increases I can't imagine any of these (along with Sparks for that matter) not having a (highly) significant impact on bleeds.

Should add that BMRN is measuring baseline bleeds by patients historical records. Both companies are doing open label trials.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up